Martin J.
- Country
- Germany
- Department
- Universitätsklinikum Giessen Klinik und Poliklinik für Neurologie
Research Overview
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Asundexian for Ischemic Stroke Prevention in Adults Post-Acute Non-Cardioembolic Stroke or High-Risk TIA
- A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke
- A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
Data & Insights
Has run more than one trial at 134 of 424 partner sites.
Specializations
Stroke Management
The investigator specializes in treating acute ischemic stroke and transient ischemic attack (TIA), with particular emphasis on preventive interventions and acute care protocols.
- Post-stroke Prevention Strategies
- Acute Stroke Treatment
- TIA Management
Focus includes evaluating novel therapeutic approaches for stroke prevention and treatment.
Neurological Disorders
Expertise extends to treating chronic inflammatory demyelinating polyneuropathy (CIDP), particularly in cases resistant to conventional treatments.
- Treatment-Resistant CIDP
- Inflammatory Neuropathies
- Neurological Disability Management
Special interest in innovative therapeutic approaches for treatment-resistant neurological conditions.
Vascular Medicine
The investigator focuses on non-cardioembolic ischemic conditions and their management through various therapeutic interventions.
- Antithrombotic Therapy
- Vascular Risk Management
- Stroke Prevention Protocols
Expertise in evaluating novel compounds for vascular condition management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.